levodopa has been researched along with dynorphins in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (17.50) | 18.2507 |
| 2000's | 19 (47.50) | 29.6817 |
| 2010's | 12 (30.00) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baronti, F; Berrettini, WH; Brughitta, G; Chase, TN; Conant, KE; Davis, TL; Giuffra, M; Iadarola, MJ; Mouradian, MM | 1 |
| Chase, TN; Engber, TM; Gerfen, CR; Kuo, S; Susel, Z | 1 |
| Bédard, PJ; Côté, PY; Grégoire, L; Parent, A; Roy, E | 1 |
| Chase, TN; Davis, TL; Giuffra, M; Mouradian, MM; Ownby, J | 1 |
| Palmiter, RD; Zhou, QY | 1 |
| Bordet, R; Carboni, S; Diaz, J; Ridray, S; Schwartz, JC; Sokoloff, P | 1 |
| Drukarch, B; Stoof, JC; van de Witte, SV; Voorn, P | 1 |
| Carta, A; Fenu, S; Morelli, M | 1 |
| Groenewegen, HJ; Van De Witte, SV; Voorn, P | 1 |
| Chen, JF; Cuellar, B; Fredduzzi, S; Impagnatiello, F; Monopoli, A; Moratalla, R; Ongini, E; Schwarzschild, MA; Xu, K | 1 |
| Carta, AR; Cauli, O; Morelli, M; Pinna, A | 1 |
| Carta, AR; Morelli, M; Pinna, A; Tronci, E | 1 |
| Baba, M; Kannari, K; Kimura, T; Maeda, T; Matsunaga, M; Tomiyama, M | 1 |
| Landry, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V | 1 |
| Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J | 1 |
| Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E | 1 |
| Ding, Y; Hwang, DY; Kang, UJ; Kim, KS; Restrepo, J; Won, L | 1 |
| Cenci, MA; Konradi, C; Strome, EM; Vercammen, L; Westin, JE | 1 |
| Cheetham, S; Jenner, P; Lane, EL | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Barnum, CJ; Bishop, C; Deak, T; Dupre, KB; Eskow, KL; Krolewski, DM; Walker, PD | 1 |
| Ares, S; Darmopil, S; De Diego, IR; Martín, AB; Moratalla, R | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Kerkerian-Le Goff, L; Khaindrava, V; Lacombe, E; Melon, C; Oueslati, A; Salin, P | 1 |
| Soghomonian, JJ; Yamamoto, N | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA | 1 |
| Burdett, TC; Cassin, JJ; Chen, JF; Fredholm, BB; Healy, B; Schwarzschild, MA; Xiao, D | 1 |
| Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A; Mammo, SE | 1 |
| Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A | 1 |
| Cai, Y; Liao, M; Liu, Z; Yang, X; Yuan, W; Zheng, R | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M | 1 |
| Mellstrom, B; Moratalla, R; Naranjo, JR; Ruiz-DeDiego, I; Vallejo, M | 1 |
| Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A | 1 |
| Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC | 1 |
| Capper-Loup, C; Kaelin-Lang, A; Paganetti, P; Sgroi, S | 1 |
| Castela, I; F Hernández, L; Moratalla, R; Obeso, JA; Ruiz-DeDiego, I | 1 |
| Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY | 1 |
| Altwal, F; Beverley, JA; F Voelkner, NM; Padovan-Neto, FE; Patterson, S; Steiner, H; West, AR | 1 |
| Andrén, PE; Bezard, E; Fridjonsdottir, E; Gunnarsdottir, H; Hulme, H; Nilsson, A; Shariatgorji, R; Svenningsson, P; Vallianatou, T; Wadensten, H; Zhang, X | 1 |
1 trial(s) available for levodopa and dynorphins
| Article | Year |
|---|---|
Dynorphin agonist therapy of Parkinson's disease.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dynorphins; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease; Pyrrolidines | 1993 |
39 other study(ies) available for levodopa and dynorphins
| Article | Year |
|---|---|
Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Topics: Adult; Aged; Aged, 80 and over; Dopamine; Dynorphins; Endorphins; Enkephalin, Methionine; Female; Homovanillic Acid; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Peptide Fragments | 1991 |
Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Drug Administration Schedule; Dynorphins; Enkephalins; Functional Laterality; Globus Pallidus; Glutamate Decarboxylase; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra | 1991 |
Mesencephalic grafts partially restore normal nigral dynorphin levels in 6-hydroxydopamine-lesioned rats treated chronically with L-dihydroxyphenylalanine.
Topics: Amphetamine; Animals; Apomorphine; Brain Tissue Transplantation; Dihydroxyphenylalanine; Dopamine Agents; Dopamine Agonists; Dynorphins; Female; Fetal Tissue Transplantation; Image Processing, Computer-Assisted; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 1995 |
Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic.
Topics: Adrenergic Fibers; Animals; Animals, Newborn; Behavior, Animal; Dopamine; Dopamine beta-Hydroxylase; Drinking Behavior; Dynorphins; Embryo, Mammalian; Feeding Behavior; Immunohistochemistry; In Situ Hybridization; Levodopa; Mesencephalon; Mice; Mice, Transgenic; Mutation; Neostriatum; Neurons; Norepinephrine; Substance P; Transgenes; Tyrosine 3-Monooxygenase | 1995 |
Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa.
Topics: Animals; Autoradiography; Behavior, Animal; Dynorphins; Gene Expression Regulation; In Situ Hybridization; Levodopa; Male; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Substance P | 1997 |
Priming with L-DOPA differently affects dynorphin and substance P mRNA levels in the striatum of 6-hydroxydopamine-lesioned rats after challenge with dopamine D1-receptor agonist.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Brain; Corpus Striatum; Dynorphins; Injections, Intraperitoneal; Injections, Subcutaneous; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; RNA, Messenger; Stereotaxic Techniques; Substance P | 1998 |
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Down-Regulation; Drug Interactions; Drug Tolerance; Dynorphins; Enkephalins; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; RNA, Messenger; Sympatholytics; Up-Regulation | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase | 2002 |
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dynorphins; Female; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Receptor, Adenosine A2A; Receptors, Purinergic P1; RNA, Messenger; Substantia Nigra | 2002 |
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Neuroprotective Agents; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; RNA, Messenger; Triazoles | 2002 |
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
Topics: Analysis of Variance; Animals; Autoradiography; Cell Count; Corpus Striatum; DNA-Binding Proteins; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Dynorphins; Early Growth Response Protein 1; Enkephalins; Gene Expression Regulation; Immediate-Early Proteins; In Situ Hybridization; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Transcriptional Activation | 2005 |
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dynorphins; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Parkinson Disease; Rats; Rats, Wistar; Serotonin Receptor Agonists | 2005 |
Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Antagonists; Dynorphins; Enkephalins; Excitatory Amino Acid Transporter 2; Gene Expression Regulation; Levodopa; Male; Neurons; Neurotensin; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Dopamine D1; Receptors, Dopamine D3; Receptors, Steroid; RNA, Messenger; Transcription Factors; Tyrosine 3-Monooxygenase | 2005 |
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic Agents; AIDS-Related Complex; Amphetamine; Analgesics, Non-Narcotic; Animals; Antiparkinson Agents; Behavior, Animal; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Functional Laterality; Homer Scaffolding Proteins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oxidopamine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger | 2006 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles | 2007 |
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Aphakia; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2007 |
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.
Topics: Animals; Benzazepines; Cell Count; Denervation; Dopamine Agents; Dopamine Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Enzyme Activation; Female; Fluorescent Antibody Technique; Immunohistochemistry; In Situ Hybridization; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neostriatum; Neurons, Efferent; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2007 |
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dynorphins; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substance P; Time | 2008 |
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Catechols; Corpus Striatum; Dynorphins; Electron Transport Complex IV; Enkephalins; Gene Expression; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nitriles; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Subthalamus | 2008 |
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists | 2009 |
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; Gene Expression Regulation; Histones; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2; Statistics as Topic; Tyrosine 3-Monooxygenase | 2009 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Electron Transport Complex IV; Gene Expression Regulation; Levodopa; Male; Nerve Net; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Protein Subunits; Rats; Rats, Wistar; RNA, Messenger | 2009 |
Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Dynorphins; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Glutamate Decarboxylase; Levodopa; Male; Neurons; Oxidopamine; Protein Precursors; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; RNA, Messenger | 2009 |
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Dyskinesias; Electron Transport Complex IV; Enkephalins; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2009 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinson Disease; Protein Precursors; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptor, Adenosine A2A; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2011 |
L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Humans; Levodopa; Mice; Neostriatum; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease.
Topics: Animals; Dynorphins; Dyskinesias; Enkephalins; Female; Immunohistochemistry; Levodopa; Male; Mass Spectrometry; Mice; Mice, Knockout; Parkinson Disease; Protein Precursors; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Brain; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Carriers; Drug Delivery Systems; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Scanning; Mitogen-Activated Protein Kinase Kinases; Nanomedicine; Nanoparticles; Particle Size; Phosphorylation; Proto-Oncogene Proteins c-fos; Rats; tau Proteins | 2012 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger | 2014 |
Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Topics: Acetylation; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Endorphins; Histones; Immunohistochemistry; Kv Channel-Interacting Proteins; Levodopa; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, AMPA; Repressor Proteins; Rotarod Performance Test | 2015 |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2015 |
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger | 2015 |
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; RNA, Messenger; Statistics as Topic; Sympatholytics; Tyrosine 3-Monooxygenase | 2016 |
Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Channelrhodopsins; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesias; Functional Laterality; Levodopa; Male; Optogenetics; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2017 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride | 2018 |
Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Tyrosine 3-Monooxygenase | 2020 |
Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
Topics: Animals; Brain; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Globus Pallidus; Levodopa; Male; Neostriatum; Parkinsonian Disorders; Rats, Wistar | 2020 |